Literature DB >> 24962954

Predictors of mortality in non-neutropenic patients with invasive pulmonary aspergillosis: does galactomannan have a role?

Alessandro Russo1, Simone Giuliano1, Antonio Vena1, Cristina Lucidi2, Marco Falcone1, Giammarco Raponi1, Manuela Merli2, Mario Venditti3.   

Abstract

We aimed to investigate the role of several host factors as predictors of mortality in non-neutropenic patients with invasive pulmonary aspergillosis (IPA). Contribution of respiratory galactomannan (GM) index was evaluated as well. In this retrospective study, we examined 27 patients with "proven" and "probable" IPA. Outcome measured was death within 6-week from diagnosis of possible IPA. Overall mortality was 33.3%. At univariate analysis, nonsurvivors were statistically more likely to be affected with cirrhosis. No independent variables predicting mortality were identified in the multivariate model. Mean bronchoalveolar lavage (BAL) GM index value in the nonsurvivor group was significantly higher. A GM index cutoff value ≥ 2.0 is able to classify patients with a poor outcome with a sensitivity of 100% and a specificity of 77%. Liver cirrhosis is a predictor of mortality in patients with IPA. GM index in BAL might be considered as a valuable tool in classifying patients at risk of poor outcome.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bronchoalveolar lavage; Chronic obstructive pulmonary disease; Cirrhosis; Galactomannan; Invasive pulmonary aspergillosis

Mesh:

Substances:

Year:  2014        PMID: 24962954     DOI: 10.1016/j.diagmicrobio.2014.05.015

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  7 in total

1.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

2.  Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients.

Authors:  Koen de Heer; Marije G Gerritsen; Caroline E Visser; Mariska Mg Leeflang
Journal:  Cochrane Database Syst Rev       Date:  2019-05-20

3.  Galactomannan in Bronchoalveolar Lavage Fluid for Diagnosis of Invasive Pulmonary Aspergillosis with Nonneutropenic Patients.

Authors:  Qidong Zhuang; Hongying Ma; Yun Zhang; Lei Chen; Li Wang; Lin Zheng; Zaichun Deng; Zhongbo Chen
Journal:  Can Respir J       Date:  2017-11-13       Impact factor: 2.409

Review 4.  Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age.

Authors:  Toine Mercier; Ellen Guldentops; Katrien Lagrou; Johan Maertens
Journal:  Front Microbiol       Date:  2018-04-04       Impact factor: 5.640

Review 5.  Challenges and Solution of Invasive Aspergillosis in Non-neutropenic Patients: A Review.

Authors:  Matteo Bassetti; Maddalena Peghin; Antonio Vena
Journal:  Infect Dis Ther       Date:  2017-12-22

6.  Methidathion Poisoning.

Authors:  Ki Hoon Kim; Se Hun Kim; Charles Her
Journal:  Korean J Crit Care Med       Date:  2017-01-17

Review 7.  Cytokine Profile of Invasive Pulmonary Aspergillosis in Severe COVID-19 and Possible Therapeutic Targets.

Authors:  Alessandro Russo; Helen Linda Morrone; Salvatore Rotundo; Enrico Maria Trecarichi; Carlo Torti
Journal:  Diagnostics (Basel)       Date:  2022-06-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.